Market Watch·Sep 5, 2026
Plastic surgery is booming with boomers. Here's how to cash in on the antiaging craze.Americans age 65 and older are suddenly the fastest-growing customers for cosmetic surgery.
AirSculpt Technologies faces a challenging fundamental outlook characterized by sustained revenue contraction and an inability to achieve consistent operating leverage, as evidenced by a recent negative operating margin of -3.18%. The company's reliance on hig...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 10, 2026 | $0.01-33.3% vs $0.01 | $43M-2.8% vs $44M |
Q2 2026 May 8, 2026 | -$0.03-50.0% vs -$0.02 | $39M+0.5% vs $39M |
Q2 2026 Apr 2, 2026 | $0.02+180.0% vs -$0.03 | $33M-3.1% vs $34M |
Q4 2025 Nov 7, 2025 | -$0.04-300.0% vs -$0.01 | $35M-12.1% vs $40M |
Americans age 65 and older are suddenly the fastest-growing customers for cosmetic surgery.
AirSculpt Technologies NASDAQ: AIRS is seeing stabilization in its core body-contouring business after several quarters of declines, while expanding services aimed at patients using GLP-1 weight-loss drugs, Chief Executive Officer Yogi Jashnani said at a Canaccord consumer conference.
AirSculpt Technologies, Inc. (AIRS) Q2 2026 Earnings Call Transcript
AirSculpt Technologies NASDAQ: AIRS reported second-quarter revenue of $42.9 million, down 2.5% from the prior-year period, as the company cited stable revenue trends, positive same-center case growth and continued investment in marketing and expanded procedure offerings.
Benchmark AIRS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for AirSculpt Technologies, Inc. (AIRS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.53 | $178.48M | -13.32 | -15.82% | -7.68% | -13.97% | — | |
| $0.67 | $87.25M | -4.21 | -10.02% | -9.79% | -47.84% | — | |
| $14.45 | $830.6M | 10.10 | -6.16% | 20.69% | 11.8% | — | |
| $0.01 | $29.44K | -0.00 | -8.54% | -21.13% | -360.33% | — | |
| $70.24 | $2.07B | -40.84 | 27.14% | -15.82% | -203.88% | — | |
| $90.77 | $116.54B | 24.34 | 8.43% | 13.93% | 10.51% | — |
AirSculpt Technologies, Inc. (AIRS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
AirSculpt Technologies, Inc. (AIRS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 12, 2026·SEC
Aug 10, 2026·SEC
May 14, 2026·SEC
Get notified when AIRS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AirSculpt Technologies, Inc. (AIRS) stock FAQ — growth, dividends, profitability & financials explained
AirSculpt Technologies, Inc. (AIRS) reported $150.7M in revenue for fiscal year 2025. This represents a 266% increase from $41.2M in 2019.
AirSculpt Technologies, Inc. (AIRS) saw revenue decline by 15.8% over the past year.
AirSculpt Technologies, Inc. (AIRS) reported a net loss of $11.7M for fiscal year 2025.
AirSculpt Technologies, Inc. (AIRS) has a return on equity (ROE) of -14.0%. Negative ROE indicates the company is unprofitable.
AirSculpt Technologies, Inc. (AIRS) generated $0.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
